Veru
$2.64
174
-$0.01-0.56% 12:29 Today
Statistics
Day High
2.66
Day Low
2.65
52W High
7.33
52W Low
2.05
Volume
6,716
Avg. Volume
-
Mkt Cap
45.18M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
May 14
$0.70
Feb 14
$0.70
Nov 13
$0.70
Aug 13
$0.70
May 13
$0.70
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
26NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.63
-0.4
-0.18
0.05
Expected EPS
-0.325
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-22.73MNet Income
Analyst Ratings
24.50Average Price Target
The highest estimate is 25.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow VERU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Merck
MRK
Mkt Cap366B
Gilead Sciences
GILD
Mkt Cap180.64B
Abbvie
ABBV
Mkt Cap451.46B
Bristol-Myers Squibb
BMY
Mkt Cap136B
AMGEN
AMGN
Mkt Cap233.78B
Johnson & Johnson
JNJ
Mkt Cap645.95B
Astrazeneca
AZN
Mkt Cap252.33B
Novartis
NVS
Mkt Cap292.35B
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
About
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Show more...
CEO
Mitchell S. Steiner
Employees
20
Country
United States
ISIN
US92536C2026
WKN
000A41ES4
Listings
0 Comments
Share your thoughts
FAQ
What is Veru stock price today?▼
The current price of VERU is $2.64 USD — it has decreased by -0.56% in the past 24 hours. Watch Veru stock price performance more closely on the chart.
What is Veru stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Veru stocks are traded under the ticker VERU.
Is Veru stock price growing?▼
VERU stock has fallen by -3.28% compared to the previous week, the month change is a +11.81% rise, over the last year Veru has showed a -19.7% decrease.
What is Veru market cap?▼
Today Veru has the market capitalization of 45.18M
When is the next Veru earnings date?▼
Veru is going to release the next earnings report on November 26, 2026.
What were Veru earnings last quarter?▼
VERU earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.32 USD resulting in a +6.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Veru revenue for the last year?▼
Veru revenue for the last year amounts to 0 USD.
What is Veru net income for the last year?▼
VERU net income for the last year is -22.73M USD.
Does Veru pay dividends?▼
Yes, VERU dividends are paid quarterly. The last dividend per share was 0.7 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Veru have?▼
As of September 04, 2026, the company has 20 employees.
In which sector is Veru located?▼
Veru operates in the Health & Wellness sector.
When did Veru complete a stock split?▼
The last stock split for Veru was on August 11, 2025 with a ratio of 1:10.
Where is Veru headquartered?▼
Veru is headquartered in MIAMI, United States.